Temporal lobe epilepsy (TLE) is a localization-related (focal) form of epilepsy in which seizures arise from foci within the temporal lobe, most commonly from its mesial aspect. The condition is one of the most widely recognized focal epilepsy syndromes and is classified by etiology as cryptogenic (of unknown cause), familial, or structural/symptomatic. TLE encompasses a broad clinical spectrum, with the temporal lobe playing a central role in processing memory, emotion, and sensory information. The condition is registered in Orphanet (Orphanet:98819) as a classified rare disease entity. Eight recognized familial subtypes exist within the TLE umbrella, including familial mesial temporal lobe epilepsy and several numerically designated familial temporal lobe epilepsy syndromes (types 1 through 8 per MONDO classification). These familial subtypes represent distinct hereditary forms of the broader condition, each with potentially differing genetic underpinnings. TLE is classified as adult-onset per the certified onset_categories field in this packet.

Seizures in TLE arise within or near the temporal lobe and manifest with a wide variety of phenomena. The certified definition describes psychic manifestations including illusions, hallucinations, dyscognitive states (characterized by impaired awareness or responsiveness during the episode), and affective experiences such as fear, déjà vu, or other emotional phenomena. The majority of complex partial seizures in epilepsy broadly originate from the temporal lobes.

Among the familial subtypes, autosomal dominant epilepsy with auditory features (ADEAF) is one recognized form for which GeneReviews data is included in this packet. GeneReviews describes ADEAF as characterized by adolescence- or adulthood-onset focal aware seizures with auditory symptoms or receptive aphasia, occurring in individuals with otherwise normal cognitive and neurologic development. These auditory features are specific to the ADEAF subtype; they are not certified as a defining characteristic of the umbrella TLE entity. No HPO phenotype associations are present in this packet for the umbrella TLE entity beyond the disease definition.

TLE is etiologically heterogeneous. The certified known_genes field for the umbrella entity (MONDO:0005115) contains no entries, reflecting that no single causative gene is certified for TLE broadly. The condition arises from a range of causes.

Familial forms of TLE represent distinct hereditary subtypes with genetic contributions. Eight such subtypes are recognized in this packet: epilepsy, familial temporal lobe types 1 through 8, and familial mesial temporal lobe epilepsy. These familial subtypes each involve heritable factors, though the specific molecular mechanisms differ across subtypes. For the ADEAF subtype specifically, GeneReviews documents a characterized causative gene; this gene is not listed in the certified known_genes field for the umbrella TLE entity, as the attribution applies specifically to that subtype.

No inheritance pattern is certified for the umbrella TLE entity in this packet (inheritance_patterns field is empty). Structural or cryptogenic causes underlie many non-familial TLE cases.

Diagnosis of TLE involves clinical assessment of seizure characteristics, including the nature of auras, focal onset features, and post-ictal phenomena. Electroencephalography (EEG) is a central diagnostic tool for identifying temporal lobe electrical activity patterns. Neuroimaging, such as MRI, is used to evaluate structural causes including hippocampal sclerosis.

For the ADEAF familial subtype specifically, the International League Against Epilepsy (ILAE) has published consensus clinical diagnostic criteria, as documented in the GeneReviews chapter present in this packet. These criteria incorporate clinical findings (focal epilepsy with auditory symptoms or aphasia), neuroimaging assessment, EEG evaluation, and family history. The differential diagnosis for ADEAF includes other genes associated with focal epilepsy syndromes, per GeneReviews. These subtype-specific criteria are not applicable to the broad TLE entity. Formal published diagnostic criteria for the umbrella TLE entity are not specified in this packet.

No drug is certified as specifically approved for the umbrella TLE entity in this packet's approved_treatments field. Antiepileptic medications form the primary pharmacological approach in TLE management broadly. Drug-resistant TLE is a recognized clinical challenge; surgical intervention is an established approach for carefully selected cases. A recruiting study (NCT01273129) is evaluating surgery as a treatment for medically intractable epilepsy.

For the ADEAF familial subtype, GeneReviews notes that no clinical practice guidelines have been published. Management for that subtype is described as based on specialist clinical experience, with antiepileptic drug therapy for seizure control as the central component. GeneReviews management guidance for ADEAF describes care provided through specialists in relevant fields.

Gene therapy and neural cell therapy approaches are under active investigation across multiple certified trials (see Research section). No gene therapy agent is certified as approved for TLE in this packet.

Prognosis in TLE varies based on etiology, seizure frequency, response to antiepileptic therapy, and the presence of an identifiable structural cause. Prognosis data for the umbrella TLE entity is not certified in this packet's natural_history or equivalent fields.

For the ADEAF familial subtype, GeneReviews documents that penetrance estimates across published family studies range from 54% to 85%, with variable penetrance reflecting methodological differences across studies. This penetrance data is specific to the ADEAF subtype and not representative of TLE broadly. The condition's classification as adult-onset (per onset_categories) reflects the predominant age of presentation, though variation exists across TLE subtypes.

TLE is an active area of clinical and translational research. This packet certifies 23 active trials on ClinicalTrials.gov, with 10 detailed trial records included. Gene therapy approaches represent a prominent research focus: AMT-260 gene therapy (NCT06063850, Phase 1, RECRUITING) is being evaluated in adults with unilateral refractory mesial temporal lobe epilepsy. UX-GIP001 is under investigation in two studies: a Phase 1 trial (NCT07572812, not yet recruiting) and an Early Phase 1 exploratory study (NCT07244328, RECRUITING) in adults with drug-resistant TLE.

A Phase 3 trial (NCT05135091, RECRUITING) is evaluating NRTX-1001 neural cell therapy for drug-resistant unilateral mesial TLE. Non-interventional studies are examining memory preservation in epilepsy surgery candidates (NCT05608408, RECRUITING) and changes in attentional control following focal seizures (NCT06466681, RECRUITING). An overnight transcranial electrical stimulation study in TLE (NCT07434986, not yet recruiting) is also listed. Sponsor profiles include both academic centers and biotech companies.

The research landscape includes 433 classified publications, with basic science/preclinical research as the dominant type. The publication base includes gene therapy publications, biomarker studies, and recent trial-related publications. Case reports number 20 and review articles number 58 in the classified set.